reCapture
your memories

Horizon 2020 Marie Sklodowska-Curie Actions
Grant Awarded To AXON Neuroscience

City: Bratislava, Slovakia. NOVEMBER 10, 2015. Neuroscientists at the biotech company AXON Neuroscience have been awarded a Horizon 2020 Marie Sklodowska-Curie Actions, European Training Network grant as part of a European consortium investigating synaptic dysfunction in Alzheimer's disease. The consortium consists of exceptional European organizations including Karolinska Institutet, University of Bordeaux, University of Milano, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), and Janssen Pharmaceuticals. The goal of the project, entitled Synaptic Dysfunction in Alzheimer's Disease (SyDAD), is to find and connect the greatest young minds in the field in order to unravel the mechanisms behind Alzheimer's disease.

The SyDAD program aims to recruit 15 Early-Stage Researchers and perform a collaborative research program, connecting academia and pharmaceutical companies. SyDAD's purpose is to train a new generation of researchers with an innovative mind-set, with the help of cutting-edge technology and world-leading experts in the research of Alzheimer's disease and synaptic biology.

The Marie Skłodowska-Curie Actions (MSCA) provide grants for researchers working across all disciplines, from life-saving healthcare to 'blue-sky' science. These grants allow research-focused organizations to host talented researchers and to create strategic partnerships with leading institutions worldwide. In addition to generous research funding, MSCA enables scientists to gain experience abroad and in the private sector, and to complete their training with competences or disciplines useful for their career development.

AXON Neuroscience is a clinical-stage biotech company based in Slovakia. It was founded in 1999 by Michal Novak, who is now the chairman of the company's Scientific Advisory Board and the site-responsible scientist for the SyDAD program. AXON Neuroscience focuses on the development of disease-modifying immunotherapeutics for Alzheimer's disease and Frontotemporal lobar degeneration.

MEDIA CONTACT:
Michael Matis
media@axon-neuroscience.eu
+421 902 161 362